8-K filed Aug 5, 2026 at 06:30 ET
Zimmer Biomet reported Q2 2026 adjusted EPS of $2.07, a 3.0% beat vs. consensus of $2.01, on revenue of $2.177B (above $2.14B consensus). Revenue grew 4.8% reported (4.0% organic constant currency). The company raised full-year 2026 guidance: reported revenue growth to 3.9%-4.9% (from 2.5%-4.5%) and adjusted EPS to $8.47-$8.59 (from $8.40-$8.55), signaling confidence in H2 momentum. The beat and guidance raise are positive, but the magnitude is modest for a large-cap medtech, and the prior quarter's cross-filing context showed a similar beat with a neutral market reaction, suggesting limited upside surprise.